* 为制药公司代工研发、生产药物的中国药明生物2269.HK周二早盘一度升4.1%，报36.28港元，早市收高2.6%。
* 投资研究机构晨星在报告中表示，首次覆盖药明生物，公允价值预估为42港元，该股被低估，预计随着产能翻倍，其收入将在未来五年重新加速，实现双位数增长。
晨星并指，由于药明生物是中国公司，且生物技术在美国被视为敏感行业，地缘政治风险导致其股价波动性更大。现阶段，考虑到药明生物与客户的良好合作记录，其假设公司能够继续承接全球项目。
* 药明生物今年迄今涨13.7%，同期恒生指数.HSI上扬1.8%。
* 恒⽣⽣物科技指数.HSBIO早市收升2.3%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 林高丽)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.